| 000 | 01077 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515234555.0 | ||
| 264 | 0 | _c20110125 | |
| 008 | 201101s 0 0 ger d | ||
| 022 | _a1435-1250 | ||
| 024 | 7 |
_a10.1007/s00393-009-0529-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoll, P | |
| 245 | 0 | 0 |
_a[Tocilizumab. What comes after TNF-blockers in clinical routine?]. _h[electronic resource] |
| 260 |
_bZeitschrift fur Rheumatologie _cSep 2010 |
||
| 300 |
_a608-17 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-6 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRheumatic Diseases _xdrug therapy |
| 700 | 1 | _aRubbert-Roth, A | |
| 700 | 1 | _aTony, H-P | |
| 773 | 0 |
_tZeitschrift fur Rheumatologie _gvol. 69 _gno. 7 _gp. 608-17 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00393-009-0529-0 _zAvailable from publisher's website |
| 999 |
_c20041069 _d20041069 |
||